References
- AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
- MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
- PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
- LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
- KardosPVogelmeierCBuhlRCriéeCPWorthHThe prospective non-interventional DACCORD study in the National COPD Registry in Germany: design and methodsBMC Pulm Med2015151225578330
- BuhlRCriéeCPKardosPA year in the life of German patients with COPD: the DACCORD observational studyInt J Chron Obstruct Pulmon Dis20161111639164627499620
- VogelmeierCWorthHBuhlR“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORDInt J Chron Obstruct Pulmon Dis20171248749428203072
- WorthHBuhlRCriéeCPKardosPMailänderCVogelmeierCThe ‘real-life’ COPD patient in Germany: the DACCORD studyRespir Med2016111647126775251
- KardosPVogelmeierCWorthHA two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational studyRespir Med2017124576428284322
- WorthHBuhlRCriéeC-PKardosPLossiNSVogelmeierCFGOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational studyRespir Med201720171317784
- WedzichaJABanerjiDChapmanKRIndacaterol–glycopyrronium versus salmeterol–fluticasone for COPDN Engl J Med2016374232222223427181606
- LandsbergerHAHawthorne RevisitedNew YorkThe New York State School of Industrial and Labor Relations1958
- McCarneyRWarnerJIliffeSvan HaselenRGriffinMFisherPThe Hawthorne effect: a randomised, controlled trialBMC Med Res Methodol2007713017608932
- JonesPWGelhornHWilsonHEffect of bronchodilator and placebo therapy on SGRQ score in patients over 3 years: difference between low/medium and high socio-economic countriesAm J Respir Crit Care Med2014189A5962.s
- DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
- KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
- CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysisRespir Res20131410024093477
- BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
- SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
- LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
- VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
- BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis20151012207221726527869
- PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
- ChalmersJDPooleCWebsterSTebbothADickinsonSGayleAAssessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD)Respir Res20181916329642882
- ChapmanKRHurstJRFrentSMLong-term triple therapy de-escalation to indacaterol/glycopyrronium in COPD Patients (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med Epub2018520
- SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
- PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDThorax201671211812526585525
- LeighRPizzichiniMMMorrisMMMaltaisFHargreaveFEPizzichiniEStable COPD: predicting benefit from high-dose inhaled corticosteroid treatmentEur Respir J200627596497116446316
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease2018 Available from: www.goldcopd.orgAccessed December 12, 2017
- HoritaNGotoAShibataYLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)Cochrane Database Syst Rev20172CD01206628185242